Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) recently hit a new 52-week high of $8.37, marking a 145.1% year-to-date gain, significantly outperforming its sector and industry. This strong performance is driven by a consistent record of positive earnings surprises, with the company reporting -$0.01 EPS against a -$0.03 consensus in its last report. Analysts project substantial future growth, anticipating EPS to turn positive at $0.21 on $349.68 million in revenue for the next fiscal year, following an estimated -$0.03 EPS on $287.18 million for the current fiscal year. With a Zacks Rank #2 (Buy) and strong Growth and Momentum Style Scores (A), the stock is considered to have further near-term upside potential.

Analysis

Xeris Biopharma Holdings (XERS) has exhibited significant price momentum, reaching a new 52-week high of $8.37 and delivering a 145.1% year-to-date return, substantially outperforming the 2.5% gain of the Zacks Medical sector. This performance is supported by strong fundamental execution, including a consistent record of beating earnings estimates over the last four quarters, with its most recent report showing an EPS of -$0.01 versus a consensus of -$0.03. The forward outlook is the primary driver, with analysts forecasting a pivotal inflection to profitability. While the current fiscal year is projected to end with a loss of -$0.03 per share, the next fiscal year is expected to deliver a positive EPS of $0.21, a 793.33% year-over-year change. This growth is complemented by strong ratings, including a Zacks Rank of #2 (Buy) and 'A' scores for both Growth and Momentum. However, a 'D' score for Value indicates the stock is not considered cheap by traditional metrics, suggesting its high valuation is predicated on achieving its aggressive future growth targets. The company also operates within the Medical - Drugs industry, which is favorably ranked in the top 33%, providing a supportive sector-wide tailwind.

Key Decisions for Investors

• Growth-oriented investors should view the combination of strong momentum, consistent earnings beats, and a clear projected path to profitability as a compelling bullish signal, even at a 52-week high.
• Given the stock's poor 'D' score for Value, investors must closely monitor the company's ability to meet its aggressive forward earnings and revenue targets, as any failure to execute could make the current valuation difficult to sustain.
• For investors seeking exposure to the strong Medical - Drugs sector but with a more balanced risk profile, it may be prudent to evaluate peer AMNEAL PHARMACEUTICALS (AMRX), which also holds a 'Buy' rating but presents a more attractive value proposition.
• The critical catalyst for XERS is its transition to profitability; therefore, upcoming quarterly reports should be scrutinized for confirmation that the company is on track to achieve the forecasted $0.21 EPS in the next fiscal year.